Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information

Abstract

ObjectiveTo estimate the incidence of muscle toxicity in patients receiving statin therapy by examining study populations, drug exposure status and outcome definitions.DesignA retrospective cohort study.Setting16 medical facilities in Japan providing information on laboratory tests performed in and claims received by their facilities between 1 April 2004 and 31 December 2010.ParticipantsA database representing a cohort of 35 903 adult statin (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin) users was studied. Use of interacting drugs (fibrates, triazoles, macrolides, amiodarone and ciclosporin) by these patients was determined.Main outcome measureStatin-associated muscle toxicity (the ‘event’) was identified based on a diagnosis of muscle-related disorders (myopathy or rhabdomyolysis) and/or abnormal elevation of creatine kinase (CK) concentrations. Events were excluded if the patients had CK elevation-related conditions other than muscle toxicity. Incidence rates for muscle toxicity were determined per 1000 person-years, with 95% CI determined by Poisson regression.ResultsA total of 18 036 patients accounted for 42 193 person-years of statin therapy, and 43 events were identified. The incidence of muscle toxicity in the patients treated with statins was 1.02 (95% CI 0.76 to 1.37)/1000 person-years. The estimates varied when outcome definitions were modified from 0.09/1000 person-years, which met both diagnosis and CK 10× greater than the upper limit of normal range (ULN) criteria, to 2.06/1000 person-years, which met diagnosis or CK 5× ULN criterion. The incidence of muscle toxicity was also influenced by the statin therapies selected, but no significant differences were observed. Among 2430 patients (13.5%) received interacting drugs with statins, only three muscle toxicity cases were observed (incidence: 1.69/1000 person-years).ConclusionsThis database study suggested that statin use is generally well tolerated and safe; however, the risk of muscle toxicity related to the use of interacting drugs requires further exploration.

Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database

“…EBM provider ® has been used effectively in multiple epidemiology studies [7, 8]. Thus, EBM provider ® was considered to be an appropriate medical database for patients who underwent an orthopedic operation of the lower extremities.…”

Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

“…Despite the fact that muscle ache and pain are most common side effects reported with statins, the incidence of myopathy, rhabdomyolysis and/or abnormal elevation of creatine kinase (CK) concentrations is still low [52]. Furthermore, when combined with warfarin, atorvastatin can cause acute rhabdomyolysis, so eze/ator should not be given with warfarin [53].…”

Associations of Polyethylenimine-Coated AN69ST Membrane in Continuous Renal Replacement Therapy with the Intensive Care Outcomes: Observations from a Claims Database from Japan

“…Data are extracted directly from electronic information systems of hospital participating in the data-sharing networks (177 hospitals, consisting of 21 hospitals with <200 beds; 110 hospitals with 200-499 beds; and 46 hospitals with ≥500 beds). Medical Data Vision Co., Ltd is a well-established data source for epidemiological and pharmacoeconomic studies from that country [9,10,11,12,13,14,15,16,17,18,19,20,21]. Medical Data Vision Co., Ltd collects data only from consenting hospitals, and these data are de-identified at source with guaranteed anonymity.…”